CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. PATENT ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.2. Restraints
3.6.3. Opportunities

CHAPTER 4 JAPAN ORPHAN DRUGS MARKET, BY DISEASE TYPE

4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ONCOLOGIC DISEASES
4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast
4.3. METABOLIC DISEASES
4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast
4.4. HEMATOLOGIC AND IMMUNOLOGIC DISEASES
4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast
4.5. INFECTIOUS DISEASES
4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast
4.6. NEUROLOGIC DISEASES
4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast
4.7. OTHER RARE DISEASES
4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast

CHAPTER 5 JAPAN ORPHAN DRUGS MARKET, BY INDICATION

5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NON-HODGKIN LYMPHOMA
5.2.1. Market size and forecast
5.3. ACUTE MYELOID LEUKEMIA
5.3.1. Market size and forecast
5.4. CYSTIC FIBROSIS
5.4.1. Market size and forecast
5.5. GLIOMA
5.5.1. Market size and forecast
5.6. PANCREATIC CANCER
5.6.1. Market size and forecast
5.7. OVARIAN CANCER
5.7.1. Market size and forecast
5.8. MULTIPLE MYELOMA
5.8.1. Market size and forecast
5.9. DUCHENNE MUSCULAR DYSTROPHY
5.9.1. Market size and forecast
5.10. GRAFT VS HOST DISEASE
5.10.1. Market size and forecast
5.11. RENAL CELL CARCINOMA
5.11.1. Market size and forecast
5.12. OTHERS
5.12.1. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. ABBVIE INC.
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. AEGERION PHARMACEUTICALS, INC. (NOVELION THERAPEUTICS INC.)
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BRISTOL-MYERS SQUIBB COMPANY
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. CELGENE CORPORATION
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. F. HOFFMANN-LA ROCHE AG
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. GLAXOSMITHKLINE PLC
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. JOHNSON & JOHNSON
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. NOVARTIS AG
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. PFIZER INC.
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. SANOFI
6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments